pegylated IFN

Phase 3Small molecule

KKaohsiung Veterans General Hospital.

pegylated IFN is one of 64 small molecule programs targeting Insulin resistance. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Chronic HepatitisActive, not recruiting

Insulin ResistancePhase 2/Phase 3

Active, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

pegylated IFN

KKaohsiung Veterans General Hospital.

Phase 3

1 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HCV1 trial

Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV

Completed·—·Phase 2·NCT02690103·37 enrolled

Insulin resistance1 trial

Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance

Unknown status·KKaohsiung Veterans General Hospital.·Phase 2/3·NCT01664845·120 enrolled

Chronic Hepatitis1 trial

Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c

Unknown status·—·Phase 3·NCT01655966·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for pegylated IFN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pegylated IFN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pegylated IFN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kaohsiung Veterans General Hospital. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKaohsiung Veterans General Hospital.

pegylated IFN

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HCV1 trial

Insulin resistance1 trial

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News